已發表論文24篇,SCI收錄21篇,總引次數近1000,H指數14。其中,第一(含共第一)或通訊作者論文11篇,4篇影響因子大於10,單篇最高引用超過430;申請/授權專利13項,第一發明人專利3項。
代表性論文:
1.Li Y#, Bai L#, Yu H, Cai D, Wang X, Huang B, Peng S, Huang M, Cao G, Kaz AM, Grady WM, Wang J, and Luo Y*. Epigenetic inactivation of α-internexin accelerates microtubule polymerization in colorectal cancer.Cancer Res. 2020; 80(23):5203-15.
2.Yao N#,Li Y#, Lei Y#, Hu N, Chen W, Yao Z, Yu M, Liu J, Ye W* and Zhang D*. A piperazidine derivative of 23-hydroxy betulinic acid induces a mitochondria-derived ROS burst to trigger apoptotic cell death in hepatocellular carcinoma cells.J Exp Clin Cancer Res. 2016; 35(1): 192.
3.Peng S#,Li Y#, Huang M, Tang G, Xie Y, Chen D, Hu Y, Yu T, Cai J, Yuan Z, Wang H, Wang H, Luo Y*, Liu X*. Metabolomics reveals that CAF-derived lipids promote colorectal cancer peritoneal metastasis by enhancing membrane fluidity.Int J Biol Sci. 2022; 18(5):1912-1932
4.Li Y#, Lei Y#, Yao N, Wang C, Hu N, Ye W, Zhang D* and Chen Z*. Autophagy and Multidrug Resistance in Cancer.Chin J Cancer(更名為Cancer Commun). 2017; 36(1): 52.
5.Lei Y#, Zhang E#, Bai L*,Li Y*. Autophagy in Cancer Immunotherapy.Cells. 2022. In press
6.Liu D#,Li Y#, Yang D, Wang C, Xu J, Yao N, Zhang X, Chen Z, Ye W* and Zhang DM*. Ganoderma lucidum derived ganoderenic acid B reverses ABCB1-mediated multidrug resistance in HepG2/ADM cells.Int J Oncol. 2015; 46(5): 2029-38.
7.Liu D#,Li Y#, Yao N, Xu J, Chen Z, Yiu A, Zhang C, Ye W*, Zhang D*. Acerinol, a cyclolanstane triterpenoid from Cimicifuga acerina, reverses ABCB1-mediated multidrug resistance in HepG2/ADM and MCF-7/ADR cells.Eur J Pharmacol. 2014; 733C: 34-44.
8.Fu B#,Li Y#, Peng S, Wang X, Hu J, Lv L, Xia C, Lu D, Qin C*. Synthesis and pharmacological characterization of glucopyranosyl-conjugated benzyl derivatives as novel selective cytotoxic agents for colon cancer.R Soc Open Sci. 2021. 8: 201642
代表性專利:
1.PLX3397在結直腸癌的治療中的用途.中國發明專利. 202210170225.6,第一發明人
2.一類化合物促皮膚損傷修複的用途.中國發明專利. 202010566166.5,第一發明人
3.化合物促皮膚損傷修複的用途.中國發明專利. 202111044412.1,第一發明人